Основная статистика
| LEI | 549300ZTF7OT1FW66Q96 |
| CIK | 1478320 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Adaptive Biotechnologies Corporation
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporati |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 5, 2025 |
Non-Employee Director Compensation Policy EXHIBIT 10.10 ADAPTIVE BIOTECHNOLOGIES CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Last updated July 24, 2025 Adaptive Biotechnologies Corporation, a Washington corporation (the “Company”), believes that the granting of cash and equity compensation to the members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, re |
|
| August 5, 2025 |
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results SEATTLE, Aug. 05, 2025 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial result |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporatio |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation |
|
| May 1, 2025 |
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports First Quarter 2025 Financial Results SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results |
|
| May 1, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2025 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation) |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| April 29, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| April 29, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| March 3, 2025 |
Insider Trading Policies and Procedures Exhibit 19 INSIDER TRADING POLICY Adopted by the Board of Directors [●], 2024 Table of Contents Section 1. |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| February 13, 2025 |
EX-99.1 2 ef20043541ex99-1.htm EXHIBIT A Exhibit A Pursuant to the instructions in Items 6 and 7 of Schedule 13G, the security being reported on by Nikko Asset Management Americas, Inc., as subsidiary to the parent holding companies listed below, are owned, or may be deemed to be beneficially owned, by its parent holding companies. 1) Sumitomo Mitsui Trust Group Inc. o A parent holding company or |
|
| February 11, 2025 |
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported fi |
|
| February 11, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorpora |
|
| January 27, 2025 |
EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0. |
|
| November 13, 2024 |
SC 13G 1 tm2427812d1sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Adaptive Biotechnologies Corporation (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 00650F109 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appro |
|
| November 13, 2024 |
SC 13G/A 1 p24-3149sc13ga.htm ADAPTIVE BIOTECHNOLOGIES CORPORATION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Adaptive Biotechnologies Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00650F109 (CUSIP Number) September 30, 2024 (Date of Event Which Require |
|
| November 8, 2024 |
SC 13G 1 ef20038337sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* ADAPTIVE BIOTECHNOLOGIES CORPORATION (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 00650F109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporat |
|
| November 7, 2024 |
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| November 5, 2024 |
SC 13G 1 adpt1028243sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* ADAPTIVE BIOTECHNOLOGIES CORPORATION (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 00650F109 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statem |
|
| October 11, 2024 |
ADPT / Adaptive Biotechnologies Corporation / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ADAPTIVE BIOTECHNOLOGIES CORPORATION (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 00650F109 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2024 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporatio |
|
| August 1, 2024 |
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial result |
|
| June 11, 2024 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 (June 07, 2024) ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction |
|
| May 28, 2024 |
ADPT / Adaptive Biotechnologies Corporation / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 00650F109 (CUSIP Number) MAY 17, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule purs |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 7, 2024 |
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports First Quarter 2024 Financial Results SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation) |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 9, 2024 Date of earliest event reported: April 4, 2024 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of |
|
| April 9, 2024 |
Executive Employment Agreement between the Company and Kyle Piskel dated April 4, 2024 Exhibit 10.1 April 1, 2024 KYLE PISKEL Re: Promotion Dear Kyle: Congratulations on your promotion to the position of Chief Financial Officer. You will report to Chad Robins, Chief Executive Officer in your new role. This letter sets out the terms of your new “at will” position with Adaptive, which will become effective on April 8, 2024. Compensation Your new full-time position is Exempt and you wi |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2024 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation |
|
| April 5, 2024 |
EXHIBIT 99.1 Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue Announces CFO transition SEATTLE, April 02, 2024 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat dis |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report April 2, 2024 (Date of earliest event reported): April 1, 2024 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| February 29, 2024 |
Adaptive Biotechnologies Corporation Policy for the Recovery of Erroneously Awarded Compensation Exhibit 97.1 ADAPTIVE BIOTECHNOLOGIES CORPORATION POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Effective Date December 1, 2023 A. OVERVIEW In accordance with the applicable rules of The Nasdaq Stock Market (the “Nasdaq Rules”), Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Rule 10D-1”), the Board of Directors (the “Board”) of Ad |
|
| February 14, 2024 |
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported fi |
|
| February 14, 2024 |
ADPT / Adaptive Biotechnologies Corporation / VIKING GLOBAL INVESTORS LP Passive Investment SC 13G/A 1 sayw2402140713ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 3) Adaptive Biotechnologies Corporation (Name of Issuer) Common stock (Title of Class of Securiti |
|
| February 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorpora |
|
| February 13, 2024 |
ADPT / Adaptive Biotechnologies Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0182-adaptivebiotechnologi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Adaptive Biotechnologies Corp Title of Class of Securities: Common Stock CUSIP Number: 00650F109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate |
|
| January 29, 2024 |
SC 13G/A 1 tm244117d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Adaptive Biotechnologies Corporation (Name of Issuer) Common stock (Title of Class of Securities) 00650F109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| November 9, 2023 |
Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update EXHIBIT 99.1 Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, tod |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporat |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report September 1, 2023 (Date of earliest event reported): September 1, 2023 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdi |
|
| August 2, 2023 |
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results SEATTLE, Aug. 02, 2023 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial result |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 (July 28, 2023) ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2023 (June 09, 2023) ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction |
|
| June 1, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro |
|
| May 9, 2023 |
EX-99.1 Exhibit 99.1 Press Release Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology - The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive’s TCR discovery platform SEATTLE, Wash., May 9, 2023 – A |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation) |
|
| May 3, 2023 |
Adaptive Biotechnologies Reports First Quarter 2023 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports First Quarter 2023 Financial Results SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2023 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation) |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 28, 2023 |
DEFA14A 1 d670966ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confident |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2023 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation |
|
| February 14, 2023 |
Calculation of Filing Fee Table Form S-8 (Form Type) Adaptive Biotechnologies Corporation (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed maximum offering price per unit Maximum aggregate offering price Fee Rate Amount of Registration Fee Equity Common stock, $0. |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2023 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorpora |
|
| February 14, 2023 |
As filed with the Securities and Exchange Commission on February 14, 2023 As filed with the Securities and Exchange Commission on February 14, 2023 Registration No. |
|
| February 14, 2023 |
Adaptive Biotechnologies Corporation Non-Employee Director Compensation Policy EXHIBIT 10.10 ADAPTIVE BIOTECHNOLOGIES CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Last updated January 26, 2023 Adaptive Biotechnologies Corporation, a Washington corporation (the “Company”), believes that the granting of cash and equity compensation to the members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| February 14, 2023 |
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results SEATTLE, Feb. 14, 2023 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported fi |
|
| February 14, 2023 |
Exhibit 21.1 List of Subsidiaries of Adaptive Biotechnologies Corporation Subsidiary Jurisdiction of Organization Digital Biotechnologies, Inc. Delaware Adaptive Biotechnologies B.V. Netherlands |
|
| February 10, 2023 |
ADPT / Adaptive Biotechnologies Corp / ARK Investment Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 9, 2023 |
ADPT / Adaptive Biotechnologies Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Adaptive Biotechnologies Corp. Title of Class of Securities: Common Stock CUSIP Number: 00650F109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporat |
|
| November 3, 2022 |
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results SEATTLE, Nov. 3, 2022 (GLOBE NEWSWIRE) ? Adaptive Biotechnologies Corporation (?Adaptive Biotechnologies?) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| September 12, 2022 |
EXHIBIT 10.1 REVENUE INTEREST PURCHASE AGREEMENT dated as of September 12, 2022 among ADAPTIVE BIOTECHNOLOGIES CORPORATION, the Purchasers from time to time party hereto and ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, as Purchaser Agent TABLE OF CONTENTS Article I. DEFINITIONS 5 Section 1.01. Definitions. 5 Article II. PURCHASE OF REVENUE INTERESTS; PAYMENTS 31 Section 2.01. Purchase of Revenue |
|
| September 12, 2022 |
EXHIBIT 99.1 Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million SEATTLE, September 12, 2022 - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a non-diluti |
|
| September 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorpor |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 3, 2022 |
Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results SEATTLE, August 3, 2022 (GLOBE NEWSWIRE) ? Adaptive Biotechnologies Corporation (?Adaptive Biotechnologies?) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial resul |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporatio |
|
| June 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation |
|
| May 4, 2022 |
Form of Performance Units Agreement and Notice of Grant of Performance Units Exhibit 10.1 ADAPTIVE BIOTECHNOLOGIES CORPORATION PERFORMANCE UNITS AGREEMENT (For U.S. Participants) Adaptive Biotechnologies Corporation has granted to the Participant named in the Notice of Grant of Performance Units (the ?Grant Notice?) to which this Performance Units Agreement (the ?Agreement?) is attached an Award consisting of Performance Units (each a ?Unit?) subject to the terms and condi |
|
| May 4, 2022 |
Adaptive Biotechnologies Reports First Quarter 2022 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports First Quarter 2022 Financial Results SEATTLE, May 4, 2022 (GLOBE NEWSWIRE) ? Adaptive Biotechnologies Corporation (?Adaptive Biotechnologies?) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results f |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation) |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporatio |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2022 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation |
|
| February 15, 2022 |
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results SEATTLE, Feb. 15, 2022 (GLOBE NEWSWIRE) ? Adaptive Biotechnologies Corporation (?Adaptive Biotechnologies?) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported fi |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| February 15, 2022 |
Exhibit 21.1 List of Subsidiaries of Adaptive Biotechnologies Corporation Subsidiary Jurisdiction of Organization Digital Biotechnologies, Inc. Delaware Adaptive Biotechnologies B.V. Netherlands |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorpora |
|
| February 14, 2022 |
ADPT / Adaptive Biotechnologies Corp / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 2) Adaptive Biotechnologies Corporation (Name of Issuer) Common stock (Title of Class of Securities) 00650F109 (CUSIP Number) Dec |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adaptive Biotechnologies Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00650F109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 9, 2022 |
ADPT / Adaptive Biotechnologies Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Adaptive Biotechnologies Corp. Title of Class of Securities: Common Stock CUSIP Number: 00650F109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2022 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporati |
|
| January 10, 2022 |
Adaptive Biotechnologies Announces Preliminary, Unaudited 2021 Revenue Results and CFO Transition EXHIBIT 99.1 Adaptive Biotechnologies Announces Preliminary, Unaudited 2021 Revenue Results and CFO Transition SEATTLE, Jan. 10, 2022 (GLOBE NEWSWIRE) ? Adaptive Biotechnologies Corporation (Nasdaq: ADPT) today reported preliminary, unaudited revenue for the year ended December 31, 2021. Total revenue for the year ended December 31, 2021 is estimated to be in the range of $153 million to $154 mill |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporat |
|
| November 3, 2021 |
Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results SEATTLE, Nov. 3, 2021 (GLOBE NEWSWIRE) ? Adaptive Biotechnologies Corporation (?Adaptive Biotechnologies?) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2021 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporatio |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 4, 2021 |
Adaptive Biotechnologies Reports Second Quarter 2021 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2021 Financial Results SEATTLE, Aug. 4, 2021 (GLOBE NEWSWIRE) ? Adaptive Biotechnologies Corporation (?Adaptive Biotechnologies?) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results |
|
| June 14, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation) |
|
| May 5, 2021 |
Adaptive Biotechnologies Reports First Quarter 2021 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports First Quarter 2021 Financial Results SEATTLE, May 5, 2021 (GLOBE NEWSWIRE) ? Adaptive Biotechnologies Corporation (?Adaptive Biotechnologies?) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results f |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| April 23, 2021 |
DEF 14A 1 adpt-def14a20210611.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 17, 2021 |
EXHIBIT 99.1 Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Katey Owen SEATTLE, March 17, 2021 – Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2021 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporatio |
|
| March 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation |
|
| March 2, 2021 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation |
|
| February 24, 2021 |
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) ? Adaptive Biotechnologies Corporation (?Adaptive Biotechnologies?) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported fi |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2021 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorpora |
|
| February 24, 2021 |
Form of Restricted Stock Unit Agreement for Non-U.S. Participants Exhibit 10.17 ADAPTIVE BIOTECHNOLOGIES CORPORATION RESTRICTED STOCK UNITS AGREEMENT (For Non-U.S. Participants) Adaptive Biotechnologies Corporation has granted to the Participant named in the Notice of Grant of Restricted Stock Units (the ?Grant Notice?) to which this Restricted Stock Units Agreement (the ?Agreement?) is attached an Award consisting of Restricted Stock Units (each a ?Unit?) subje |
|
| February 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| February 24, 2021 |
Exhibit 21.1 List of Subsidiaries of Adaptive Biotechnologies Corporation Subsidiary Jurisdiction of Organization Spin Technologies, Inc. Delaware |
|
| February 24, 2021 |
Form of Stock Option Agreement for Non-U.S. Participants Exhibit 10.16 ADAPTIVE BIOTECHNOLOGIES CORPORATION STOCK OPTION AGREEMENT (For Non-U.S. Participants) Adaptive Biotechnologies Corporation (the ?Company?) has granted to the Participant named in the Notice of Grant of Stock Option (the ?Grant Notice?) to which this Stock Option Agreement (the ?Option Agreement?) is attached an option (the ?Option?) to purchase certain shares of Stock upon the term |
|
| February 24, 2021 |
Adaptive Biotechnologies Corporation Non-Employee Director Compensation Policy EXHIBIT 10.12 ADAPTIVE BIOTECHNOLOGIES CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Last updated February 14, 2021 Adaptive Biotechnologies Corporation, a Washington corporation (the ?Company?), believes that the granting of cash and equity compensation to the members of its Board of Directors (the ?Board,? and members of the Board, the ?Directors?) represents an effective tool to attract |
|
| February 16, 2021 |
Adaptive Biotechnologies Corporation SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adaptive Biotechnologies Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00650F109 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 1) Adaptive Biotechnologies Corporation (Name of Issuer) Common stock (Title of Class of Securities) 00650F109 (CUSIP Number) D |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Adaptive Biotechnologies Corp. Title of Class of Securities: Common Stock CUSIP Number: 00650F109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d |
|
| January 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporat |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorpora |
|
| November 10, 2020 |
Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results |
|
| November 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorpora |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| October 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporati |
|
| August 21, 2020 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporati |
|
| August 21, 2020 |
424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-239854 CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(2) Amount of Registration Fee(3) Common Stock, par value $0.0001 per share 33,493,708 $38.96 $1,304,914,864 $169,378 (1) Pursuant to |
|
| August 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporati |
|
| August 10, 2020 |
Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Second Quarter 2020 Financial Results SEATTLE, Aug. 10, 2020 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial result |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| August 10, 2020 |
Form of Executive Severance Agreement between the Registrant and certain of its executive officers EXHIBIT 10.1 ADAPTIVE BIOTECHNOLOGIES CORPORATION EXECUTIVE SEVERANCE AGREEMENT This Executive Severance Agreement (the “Agreement”) is entered into by and between Adaptive Biotechnologies Corporation, a Washington corporation (the “Company”), and [Insert Name] (“Executive”). The terms of this Agreement will become effective on the Effective Date (as defined below). 1.At-Will Employment. The parti |
|
| July 16, 2020 |
Adaptive Biotechnologies Announces Pricing of Public Offering of Common Stock EXHIBIT 99.2 Adaptive Biotechnologies Announces Pricing of Public Offering of Common Stock SEATTLE, Wash., July 15, 2020 – Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of an underwritten public offering |
|
| July 16, 2020 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-239854 CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Amount to be Registered(1) Maximum Offering Price Per Share Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value $0.0001 per share 9,200,000 $40.00 $368,000,000 $47,767 (1) Includes 1,200,000 shares of common sto |
|
| July 16, 2020 |
EXHIBIT 1.1 Adaptive Biotechnologies Corporation Common Stock Underwriting Agreement July 15, 2020 J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC BofA Securities, Inc. As representatives of the several Underwriters named in Schedule II hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 c/o |
|
| July 16, 2020 |
Adaptive Biotechnologies Announces Proposed Public Offering of Common Stock EX-99.1 4 adpt-ex9916.htm EX-99.1 PRESS RELEASE DATED JULY 14, 2020 EXHIBIT 99.1 Adaptive Biotechnologies Announces Proposed Public Offering of Common Stock SEATTLE, Wash., July 14, 2020 – Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat diseas |
|
| July 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation |
|
| July 14, 2020 |
Form of indenture for senior debt securities and the related form of senior debt security. EX-4.3 Exhibit 4.3 ADAPTIVE BIOTECHNOLOGIES CORPORATION ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE ONE - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 SECTION 101. Definitions 2 SECTION 102. Compliance Certificates and Opinions 11 SECTION 103. Form of Documents Delivered to Trustee 12 SECTION 104. Acts of Holders 12 SE |
|
| July 14, 2020 |
S-3ASR Table of Contents As filed with the Securities and Exchange Commission on July 14, 2020 Registration No. |
|
| July 14, 2020 |
EX-4.4 Exhibit 4.4 ADAPTIVE BIOTECHNOLOGIES CORPORATION ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE ONE - DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 SECTION 101. Definitions 2 SECTION 102. Compliance Certificates and Opinions 12 SECTION 103. Form of Documents Delivered to Trustee 13 SECTION 104. Acts of Holders |
|
| July 14, 2020 |
Subject to Completion, dated July 14, 2020 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-239854 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| June 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation |
|
| June 16, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation |
|
| May 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation) |
|
| May 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 12, 2020 |
Adaptive Biotechnologies Reports First Quarter 2020 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports First Quarter 2020 Financial Results SEATTLE, May 12, 2020 – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter e |
|
| May 5, 2020 |
Exhibit 99.1 Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing LabCorp, through its Covance drug development business, will provide a safe, in-person COVID-19 sample collection service from the convenience of patients? homes De-identified data about immune response to COVID-19 will be made freely available |
|
| May 5, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporation) |
|
| April 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 20, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporatio |
|
| March 20, 2020 |
EXHIBIT 99.1 March 20, 2020 Adaptive Biotechnologies and Microsoft expand partnership to decode COVID-19 immune response and provide open data access Differentiated approach may improve detection methods and inform vaccine discovery for COVID-19 Other industry leaders including LabCorp, through its Covance drug development business, Illumina, and Providence join forces to accelerate this critical |
|
| February 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| February 26, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorpora |
|
| February 26, 2020 |
EXHIBIT 4.3 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description (this ?Description?) of our common stock is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our Articles of Incorporation and Bylaws, each of which have been filed with the Securities an |
|
| February 26, 2020 |
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2019 Financial Results EXHIBIT 99.1 Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2019 Financial Results SEATTLE, Feb. 26, 2020 (GLOBE NEWSWIRE) ? Adaptive Biotechnologies Corporation (?Adaptive Biotechnologies?) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported fi |
|
| February 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorpora |
|
| February 14, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Adaptive Biotechnologies Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 00650F109 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Adaptive Biotechnologies Corporation (Name of Issuer) Common stock (Title of Class of Securities) 00650F109 (CUSIP Number) December 31, 2019 (Dat |
|
| January 27, 2020 |
Adaptive Announces Preliminary Unaudited Revenue for Full Year 2019 EXHIBIT 99.1 Adaptive Announces Preliminary Unaudited Revenue for Full Year 2019 SEATTLE, Wash., January 21, 2020 ? Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today preliminary unaudited revenue for the full year 2019. P |
|
| January 27, 2020 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorpor |
|
| January 24, 2020 |
EXHIBIT 99.2 Recent Developments Preliminary Estimates for Year Ended December 31, 2019 Our financial statements for the year ended December 31, 2019 are not yet available. Accordingly, the information presented below reflects our preliminary estimates subject to the completion of our financial closing procedures and any adjustments that may result from the completion of the audit of our financial |
|
| January 24, 2020 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-235989 8,000,000 Shares Common Stock The selling shareholders identified in the ?Principal and Selling Shareholders? section are offering 8,000,000 shares of our common stock. We will not receive any proceeds from the sale of the shares to be offered by the selling shareholders. Our common stock is listed on The Nasdaq Global |
|
| January 24, 2020 |
Adaptive Announces Proposed Public Offering of Common Stock EXHIBIT 99.1 Adaptive Announces Proposed Public Offering of Common Stock SEATTLE, Wash., January 21, 2020 ? Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the commencement of a proposed underwritten public offering of |
|
| January 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporat |
|
| January 24, 2020 |
Adaptive Announces Pricing of Public Offering of Common Stock EXHIBIT 99.3 Adaptive Announces Pricing of Public Offering of Common Stock SEATTLE, Wash., January 23, 2020 ? Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of an underwritten public offering of 8,000,000 s |
|
| January 22, 2020 |
As filed with the Securities and Exchange Commission on January 22, 2020. As filed with the Securities and Exchange Commission on January 22, 2020. Registration No. 333-235989 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Washington 2836 27-0907024 (State or other jurisdi |
|
| January 22, 2020 |
Form of Underwriting Agreement Exhibit 1.1 Adaptive Biotechnologies Corporation Common Stock Underwriting Agreement , 2020 J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC BofA Securities, Inc. As representatives of the several Underwriters named in Schedule II hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 c/o BofA S |
|
| January 21, 2020 |
January 21, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Adaptive Biotechnologies Corporation Registration Statement on Form S-1 File No. 333-235989 Acceleration Request Requested Date: January 23, 2020 Requested Time: 4:30 p.m., Eastern Time Ladies and Gentlemen: Pursuant to Rule 460 |
|
| January 21, 2020 |
January 21, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Adaptive Biotechnologies Corporation Registration Statement on Form S-1 File No. 333-235989 Acceleration Request Requested Date: January 23, 2020 Requested Time: 4:30 p.m., Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 |
|
| January 21, 2020 |
Table of Contents As filed with the Securities and Exchange Commission on January 21, 2020. |
|
| January 9, 2020 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on January 9, 2020. |
|
| January 8, 2020 |
EXHIBIT 99.1 Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ? for Monitoring MRD in Patients With Chronic Lymphocytic Leukemia SEATTLE, Wash., January 8, 2020 ? Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, |
|
| January 8, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2020 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorporati |
|
| November 12, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 adpt-8k20191112.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or O |
|
| November 12, 2019 |
Adaptive Biotechnologies Corporation Reports Third Quarter 2019 Financial Results Exhibit 99.1 Adaptive Biotechnologies Corporation Reports Third Quarter 2019 Financial Results SEATTLE, November 12, 2019 (GLOBE NEWSWIRE) ? Adaptive Biotechnologies Corporation (?Adaptive Biotechnologies?) (Nasdaq: ADPT) today reported financial results for the quarter ended September 30, 2019. ?During the third quarter, we continued to make strong progress across our existing products and our pi |
|
| November 12, 2019 |
Exhibit 10.3 Confidential Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. IVD TEST KIT development AND SUPPLY AGREEMENT This IVD Test Kit Development and Supply Agreement (the ?Agreement?) is effective as of the date of last signature below (the ?Effective Date?) and is made by and between Illumin |
|
| November 12, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I. |
|
| September 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 24, 2019 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-38957 27-0907024 (State or Other Jurisdiction of Incorpor |
|
| September 24, 2019 |
Exhibit 99.1 Adaptive Biotechnologies Enters Partnership with Illumina to Develop Distributable IVD Test Kits for clonoSEQ and immunoSEQ Dx Partnership Will Enable Physicians to Order Clinical Immunodiagnostic Testing that Can Be Performed in Local Laboratories SEATTLE, Wash., September 24, 2019 ? Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that ai |
|
| August 13, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2019 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Washington 001-38957 27-0907024 (State or other jurisdiction of incorporati |
|
| August 13, 2019 |
Adaptive Biotechnologies Corporation Reports Second Quarter 2019 Financial Results Exhibit 99.1 Adaptive Biotechnologies Corporation Reports Second Quarter 2019 Financial Results SEATTLE, August 13, 2019 (GLOBE NEWSWIRE) ? Adaptive Biotechnologies Corporation (?Adaptive Biotechnologies?) (Nasdaq: ADPT) today reported financial results for the quarter ended June 30, 2019. ?At Adaptive, we are translating the genetics of the adaptive immune system into clinical products to transfo |
|
| August 13, 2019 |
Exhibit 10.12 ADAPTIVE BIOTECHNOLOGIES CORPORATION 2019 EQUITY INCENTIVE PLAN Table of Contents Page 1. Establishment, Purpose and Term of Plan1 1.1 Establishment1 1.2 Purpose1 1.3 Term of Plan1 2. Definitions and Construction1 2.1 Definitions1 2.2 Construction8 3. Administration8 3.1 Administration by the Committee8 3.2 Authority of Officers9 3.3 Administration with Respect to Insiders9 3.4 Power |
|
| August 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 ( State or other jurisdiction of incorporation or organization) (I. |
|
| August 7, 2019 |
Exhibit 10.2 Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made this 2nd day of August, 2019, between ARE-SEATTLE NO. 12, LLC, a Delaware limited liability company (?Landlord?), and ADAPTIVE BIOTECHNOLOGIES CORPORATION, a Washington corporat |
|
| August 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2019 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Washington 001-38957 27-0907024 (State or other jurisdiction of incorporatio |
|
| August 7, 2019 |
Exhibit 99.1 Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattle?s Growing Biotech Hub Development of the waterfront office space and research facility by Alexandria Real Estate Equities, Inc. is underway with occupancy expected in 2021 SEATTLE, Wash., August 7, 2019 ? Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a co |
|
| August 7, 2019 |
Exhibit 10.1 Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed SIXTH AMENDMENT TO LEASE THIS SIXTH AMENDMENT TO LEASE (this ?Sixth Amendment?) is made as of August 2, 2019, by and between ARE-SEATTLE NO. 11, LLC, a Delaware limited liability company (?Landlord?), and ADAPTIVE BIOTECHNOLOGIES CORPORAT |
|
| August 2, 2019 |
Exhibit 99.1 Adaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood Cancers SEATTLE, July 31, 2019 ? Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (?Adaptive?), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system with the goal o |
|
| August 2, 2019 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2019 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Washington 001-38957 27-0907024 (State or other jurisdiction of incorporation |
|
| July 1, 2019 |
Adaptive Biotechnologies Announces Pricing of Initial Public Offering Exhibit 99.1 Adaptive Biotechnologies Announces Pricing of Initial Public Offering SEATTLE, Wash, June 26, 2019 ? Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (?Adaptive?), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnostics and therapeutics to improve patient lives, today announced the pricing |
|
| July 1, 2019 |
Amended and Restated Articles of Incorporation Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF ADAPTIVE BIOTECHNOLOGIES CORPORATION ARTICLE 1 NAME The name of the corporation is Adaptive Biotechnologies Corporation. ARTICLE 2 DURATION The corporation is organized under the Washington Business Corporation Act (the ?Act?) and shall have perpetual existence. ARTICLE 3 PURPOSE AND POWERS The purpose and powers of the corporation are |
|
| July 1, 2019 |
Exhibit 99.2 Adaptive Biotechnologies Announces Closing of Initial Public Offering and Full Exercise of the Underwriters? Option to Purchase Additional Shares SEATTLE, Wash, July 1, 2019 ? Adaptive Biotechnologies Corporation (Nasdaq:ADPT) (?Adaptive?), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnost |
|
| July 1, 2019 |
Sequenta, Inc. 2008 Stock Plan and form of award agreement thereunder. Exhibit 99.1 SEQUENTA, INC. 2008 STOCK PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants and to promote the success of the Company?s business. The Plan permits the grant of Options and Restricted Stock as the Administrator |
|
| July 1, 2019 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ADAPTIVE BIOTECHNOLOGIES CORPORATION (Incorporated under the Laws of Washington) (Effective July 1, 2019) TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II SHAREHOLDERS 2 2.1 Annual Meeting 2 2.2 Special Meetings 2 2.3 Notice of Meetings 2 2.4 Quorum; Vote Requirement 3 2.5 Adjournments 3 2.6 Record Date 4 2.7 Organization of Meetings 4 2.8 Proxie |
|
| July 1, 2019 |
As filed with the Securities and Exchange Commission on July 1, 2019 As filed with the Securities and Exchange Commission on July 1, 2019 Registration No. |
|
| July 1, 2019 |
8-K 1 d27753d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 26, 2019 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Washington 1-38957 27-0907024 (State or other jurisdi |
|
| June 27, 2019 |
15,000,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-231838 PROSPECTUS 15,000,000 Shares Common Stock This is an initial public offering of shares of common stock of Adaptive Biotechnologies Corporation. We are offering 15,000,000 shares of our common stock to be sold in this offering. Prior to this offering, there has been no public market for our common stock. The initial publ |
|
| June 26, 2019 |
Table of Contents As filed with the Securities and Exchange Commission on June 26, 2019. |
|
| June 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact name of registrant as specified in its charter) Washington 27-0907024 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Ide |
|
| June 24, 2019 |
June 24, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Sharon Blume Justin Dobbie Andi Carpenter Julie Griffith Re: Adaptive Biotechnologies Corporation Registration Statement on Form S-1 File No. 333-231838 Acceleration Request Requested Date: Wednesday, June 26, 2019 Requested Time: 4:00 p.m., Eastern D |
|
| June 24, 2019 |
June 24, 2019 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Sharon Blume Justin Dobbie Andi Carpenter Julie Griffith Re: Adaptive Biotechnologies Corporation Registration Statement on Form S-1 File No. 333-231838 Acceleration Request Requested Date: Wednesday, June 26, 2019 Requested Time: 4:00 p.m., Eastern D |
|
| June 19, 2019 |
As filed with the Securities and Exchange Commission on June 19, 2019. Table of Contents As filed with the Securities and Exchange Commission on June 19, 2019. |
|
| June 17, 2019 |
Exhibit 3.2 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF ADAPTIVE BIOTECHNOLOGIES CORPORATION ARTICLE 1 NAME The name of the corporation is Adaptive Biotechnologies Corporation. ARTICLE 2 DURATION The corporation is organized under the Washington Business Corporation Act (the ?Act?) and shall have perpetual existence. ARTICLE 3 PURPOSE AND POWERS The purpose and powers of the corporation are |
|
| June 17, 2019 |
Form of Amended and Restated Bylaws (to be effective upon the closing of this offering) Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF ADAPTIVE BIOTECHNOLOGIES CORPORATION (Incorporated under the Laws of Washington) (Effective , 2019) TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II SHAREHOLDERS 2 2.1 Annual Meeting 2 2.2 Special Meetings 2 2.3 Notice of Meetings 2 2.4 Quorum; Vote Requirement 3 2.5 Adjournments 3 2.6 Record Date 4 2.7 Organization of Meetings 4 2.8 Proxies 4 2. |
|
| June 17, 2019 |
Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan Exhibit 10.17 ADAPTIVE BIOTECHNOLOGIES CORPORATION 2019 EMPLOYEE STOCK PURCHASE PLAN TABLE OF CONTENTS Page 1. Establishment, Purpose and Term of Plan 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction 1 2.1 Definitions 1 2.2 Construction 6 3. Administration 6 3.1 Administration by the Committee 6 3.2 Authority of Officers 6 3.3 Power to Adopt Sub-Plans 6 3.4 Po |
|
| June 17, 2019 |
Adaptive Biotechnologies Corporation Non-Employee Director Compensation Policy Exhibit 10.14 ADAPTIVE BIOTECHNOLOGIES CORPORATION OUTSIDE DIRECTOR COMPENSATION POLICY Adopted and approved June 10, 2019 Adaptive Biotechnologies Corporation, a Washington corporation (the ?Company?), believes that the granting of cash and equity compensation to the members of its Board of Directors (the ?Board,? and members of the Board, the ?Directors?) represents an effective tool to attract, |
|
| June 17, 2019 |
Exhibit 10.16 ADAPTIVE BIOTECHNOLOGIES CORPORATION 2019 EQUITY INCENTIVE PLAN TABLE OF CONTENTS Page 1. Establishment, Purpose and Term of Plan 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction 1 2.1 Definitions 1 2.2 Construction 8 3. Administration 8 3.1 Administration by the Committee 8 3.2 Authority of Officers 9 3.3 Administration with Respect to Insiders |
|
| June 17, 2019 |
Form of Underwriting Agreement Exhibit 1.1 Adaptive Biotechnologies Corporation Common Stock Underwriting Agreement , 2019 Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC BofA Securities, Inc. As representatives of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282-2198 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o BofA Se |
|
| June 17, 2019 |
As filed with the Securities and Exchange Commission on June 17, 2019. Table of Contents As filed with the Securities and Exchange Commission on June 17, 2019. |
|
| June 17, 2019 |
Master Terms & Conditions of Sale between Illumina, Inc. and the Registrant, dated May 28, 2019 Exhibit 10.3 Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. Master Terms and Conditions of Sale (Illumina Advantage Products) These MASTER TERMS AND CONDITIONS OF SALE (these ?Terms?) are entered into effective as of May 28, 2019 (the ?Effective Date?) by and between Illumina, Inc., a Delaware co |
|
| June 17, 2019 |
DLA Piper LLP (US) 701 Fifth Avenue Suite 6900 Seattle, Washington 98104-7044 www. |
|
| June 4, 2019 |
CONFIDENTIAL TREATMENT REQUESTED BY ADAPTIVE BIOTECHNOLOGIES CORPORATION CERTAIN PORTIONS OF THIS LETTER AS FILED VIA EDGAR HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. |
|
| May 30, 2019 |
Warrant to Purchase Common Stock, dated July 18, 2013, issued by the Registrant to Imdaptive, Inc. Exhibit 4.3 Warrant THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR UNDER THE SECURITIES LAWS OF APPLICABLE STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECU |
|
| May 30, 2019 |
Exhibit 10.1 Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. CONFIDENTIAL EXECUTION COPY STRATEGIC COLLABORATION AND LICENSE AGREEMENT THIS STRATEGIC COLLABORATION AND LICENSE AGREEMENT (?Agreement?) is made and entered into as of December 19, 2018 (?Execution Date?), by and between Adaptive Biote |
|
| May 30, 2019 |
Exhibit 10.8 ? 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.com , 2019 [Employee Name] [Employee Address] [Employee Address] Re: Employment Agreement Dear [Employee Name]: This letter agreement (this ?Agreement?) confirms the terms of your employment with Adaptive Biotechnologies Corporation, a Washington corporation (the ?Company?). 1. Title and Cash Compensation Yo |
|
| May 30, 2019 |
Exhibit 10.18 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made this 21 day of July, 2011, between ARE-SEATTLE NO. 11, LLC, a Delaware limited liability company (?Landlord?), and ADAPTIVE TCR CORPORATION, a Washington corporation (?Tenant?). Address: 1551 Eastlake Avenue, Seattle, Washington Premises: That portion of the second floor of the Project, containing approximately 7,724 rentabl |
|
| May 30, 2019 |
Executive Severance Agreement between the Registrant and Chad Cohen, dated May 1, 2019 Exhibit 10.10 ? 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.com May 1, 2019 Chad Cohen [address] Re: Executive Severance Agreement Dear Chad: This letter agreement (this ?Agreement?) confirms the terms of your severance rights in connection with your employment with Adaptive Biotechnologies Corporation, a Washington corporation (the ?Company?), and supplements that |
|
| May 30, 2019 |
Master Collaboration Agreement between Adaptimmune Limited and the Registrant, dated July 10, 2015 Exhibit 10.4 Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. MASTER COLLABORATION AGREEMENT This Master Collaboration Agreement (this ?Agreement?) is made effective as of July 10, 2015 by and between ADAPTIVE BIOTECHNOLOGIES CORPORATION, a Washington corporation (?Adaptive?), and Adaptimmune Limit |
|
| May 30, 2019 |
Warrant dated April 21, 2014, issued by the Registrant to Alexandria Equities, LLC Exhibit 4.4 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, S |
|
| May 30, 2019 |
Exhibit 10.9 ? 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.com [Date] [Non-Employee Director Name] [Non-Employee Director Address] [Non-Employee Director Address] Re: Restated Non-Employee Director Change in Control Agreement Dear [Non-Employee Director Name]: On behalf of Adaptive Biotechnologies Corporation (the ?Company?), I am pleased to offer you the following |
|
| May 30, 2019 |
Exhibit 10.5 May 8, 2019 Viking Global Equities II LP Viking Global Equities Master Ltd. Viking Global Opportunities Illiquid Investments Sub-Master LP Viking Long Fund Master Ltd. 55 Railroad Ave. Greenwich, CT 06830 Attention: Katerina Novak Email: [email protected] RE: Amended and Restated Standstill and Support Obligations Reference is made to that certain letter agreement regardin |
|
| May 30, 2019 |
[Remainder of page intentionally blank. Signature page follows.] DLA Piper LLP (US) 701 Fifth Avenue Suite 6900 Seattle, Washington 98104-7044 www. |
|
| May 30, 2019 |
Exhibit 10.15 ADAPTIVE BIOTECHNOLOGIES CORPORATION 2009 EQUITY INCENTIVE PLAN TABLE OF CONTENTS Page 1. Establishment, Purpose and Term of Plan 1 1.1 Establishment 1 1.2 Purpose 1 1.3 Term of Plan 1 2. Definitions and Construction 1 2.1 Definitions 1 2.2 Construction 8 3. Administration 8 3.1 Administration by the Committee 8 3.2 Authority of Officers 9 3.3 Administration with Respect to Insiders |
|
| May 30, 2019 |
Exhibit 10.6 MASTER SERVICES AGREEMENT THIS MASTER SERVICES AGREEMENT (the ?Agreement?) effective this 5th day of August, 2015 (the ?Effective Date?), is made and entered into by and between Adaptive Biotechnologies Corporation, a Washington corporation having a business address at 1551 Eastlake Avenue East, Suite 200 Seattle, WA 98102, on behalf of itself and its subsidiaries (together with its s |
|
| May 30, 2019 |
Warrant to Purchase Stock, dated June 5, 2012, issued by the Registrant to Silicon Valley Bank Exhibit 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, S |
|
| May 30, 2019 |
Exhibit 10.13 ADAPTIVE BIOTECHNOLOGIES CORPORATION INDEMNIFICATION AGREEMENT This Indemnification Agreement (the ?Agreement?) is entered into on , 20 , between Adaptive Biotechnologies Corporation, a Washington corporation (the ?Company?), and the undersigned officer and/or director of the Company (?Indemnitee?), for good and valuable consideration as set forth below. RECITALS A. The Company recog |
|
| May 30, 2019 |
Exhibit 10.2 Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXECUTION VERSION MICROSOFT ARTIFICIAL INTELLIGENCE & RESEARCH GROUP STRATEGIC COLLABORATION AGREEMENT This Strategic Collaboration Agreement (this ?Agreement?) is made and entered into as of the last signature date written below (the ?E |
|
| May 30, 2019 |
Amended and Restated Articles of Incorporation of the Registrant, as currently in effect Exhibit 3.1 CERTIFICATE OF OFFICER REGARDING AMENDED AND RESTATED ARTICLES OF INCORPORATION OF ADAPTIVE BIOTECHNOLOGIES CORPORATION Adaptive Biotechnologies Corporation, a Washington corporation, by Chad M. Robins, its duly elected and qualified Chief Executive Officer, hereby delivers to the Secretary of State of the State of Washington for filing Amended and Restated Articles of Incorporation in |
|
| May 30, 2019 |
Power of Attorney (included on the signature page) Table of Contents As filed with the Securities and Exchange Commission on May 30, 2019. |
|
| May 30, 2019 |
Bylaws of the Registrant, as currently in effect Exhibit 3.3 BYLAWS OF ADAPTIVE BIOTECHNOLOGIES CORPORATION Originally adopted on September 14, 2009 Amendments are listed on p. i ADAPTIVE BIOTECHNOLOGIES CORPORATION AMENDMENTS TO BYLAWS Article Effect of Amendment Date of Amendment II, Sec. 2.2 Board ratifies, confirms and approves that incorporator set the number of directors comprising the Board initially at one (1) member. 09/14/09 Board rati |
|
| May 30, 2019 |
Exhibit 4.1 ADAPTIVE BIOTECHNOLOGIES CORPORATION SEVENTH AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT May 30, 2019 SEVENTH AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS SEVENTH AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT (this ?Agreement?) is made as of May 30, 2019, by and between (i) Adaptive Biotechnologies Corporation, a Washington corporation (the ?Company?), (ii) each of the |
|
| May 30, 2019 |
Exhibit 10.7 ? 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.com , 2019 [Employee Name] [Employee Address] [Employee Address] Re: Employment Agreement Dear [Employee Name]: This letter agreement (this ?Agreement?) confirms the terms of your employment with Adaptive Biotechnologies Corporation, a Washington corporation (the ?Company?). 1. Title and Cash Compensation Yo |
|
| May 30, 2019 |
Executive Severance Agreement between the Registrant and Charles Sang, dated May 1, 2019 Exhibit 10.12 ? 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.com May 1, 2019 Charles Sang [address] Re: Executive Severance Agreement Dear Charles: This letter agreement (this ?Agreement?) confirms the terms of your severance rights in connection with your employment with Adaptive Biotechnologies Corporation, a Washington corporation (the ?Company?), and supplements |
|
| May 30, 2019 |
Executive Severance Agreement between the Registrant and Lance Baldo, MD, dated April 22, 2019 Exhibit 10.11 ? 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.com April 22, 2019 Lance Baldo, MD [address] Re: Executive Severance Agreement Dear Lance: This letter agreement (this ?Agreement?) confirms the terms of your severance rights in connection with your employment with Adaptive Biotechnologies Corporation, a Washington corporation (the ?Company?), and suppleme |
|
| May 8, 2019 |
Exhibit 10.9 ? 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.com [Date] [Non-Employee Director Name] [Non-Employee Director Address] [Non-Employee Director Address] Re: Restated Non-Employee Director Change in Control Agreement Dear [Non-Employee Director Name]: On behalf of Adaptive Biotechnologies Corporation (the ?Company?), I am pleased to offer you the following |
|
| May 8, 2019 |
MICROSOFT ARTIFICIAL INTELLIGENCE & RESEARCH GROUP STRATEGIC COLLABORATION AGREEMENT Exhibit 10.2 Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. EXECUTION VERSION MICROSOFT ARTIFICIAL INTELLIGENCE & RESEARCH GROUP STRATEGIC COLLABORATION AGREEMENT This Strategic Collaboration Agreement (this ?Agreement?) is made and entered into as of the last signature date written below (the ?E |
|
| May 8, 2019 |
MASTER COLLABORATION AGREEMENT Exhibit 10.4 Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. MASTER COLLABORATION AGREEMENT This Master Collaboration Agreement (this ?Agreement?) is made effective as of July 10, 2015 by and between ADAPTIVE BIOTECHNOLOGIES CORPORATION, a Washington corporation (?Adaptive?), and Adaptimmune Limit |
|
| May 8, 2019 |
Exhibit 10.11 ? 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.com , 2019 [Employee Name] [Employee Address] [Employee Address] Re: Employment Agreement Dear [Employee Name]: This letter agreement (this ?Agreement?) confirms the terms of your employment with Adaptive Biotechnologies Corporation, a Washington corporation (the ?Company?). 1. Title and Cash Compensation Y |
|
| May 8, 2019 |
Exhibit 10.13 ? 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.com May 1, 2019 Chad Cohen [address] Re: Executive Severance Agreement Dear Chad: This letter agreement (this ?Agreement?) confirms the terms of your severance rights in connection with your employment with Adaptive Biotechnologies Corporation, a Washington corporation (the ?Company?), and supplements that |
|
| May 8, 2019 |
STRATEGIC COLLABORATION AND LICENSE AGREEMENT Exhibit 10.1 Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly disclosed. CONFIDENTIAL EXECUTION COPY STRATEGIC COLLABORATION AND LICENSE AGREEMENT THIS STRATEGIC COLLABORATION AND LICENSE AGREEMENT (?Agreement?) is made and entered into as of December 19, 2018 (?Execution Date?), by and between Adaptive Biote |
|
| May 8, 2019 |
Exhibit 10.14 ? 1551 Eastlake Ave E, Ste 200 Seattle, WA 98102 206.659.0067 adaptivebiotech.com April 22, 2019 Lance Baldo, MD [address] Re: Executive Severance Agreement Dear Lance: This letter agreement (this ?Agreement?) confirms the terms of your severance rights in connection with your employment with Adaptive Biotechnologies Corporation, a Washington corporation (the ?Company?), and suppleme |
